CFTR and Gastrointestinal Cancers: An Update
Open Access
- 25 May 2022
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (6) , 868
Abstract
Cystic Fibrosis (CF) is a disease caused by mutations in the CFTR gene that severely affects the lungs as well as extra-pulmonary tissues, including the gastrointestinal (GI) tract. CFTR dysfunction resulting from either mutations or the downregulation of its expression has been shown to promote carcinogenesis. An example is the enhanced risk for several types of cancer in patients with CF, especially cancers of the GI tract. CFTR also acts as a tumor suppressor in diverse sporadic epithelial cancers in many tissues, primarily due to the silencing of CFTR expression via multiple mechanisms, but especially due to epigenetic regulation. This review provides an update on the latest research linking CFTR-deficiency to GI cancers, in both CF patients and in sporadic GI cancers, with a particular focus on cancer of the intestinal tract. It will discuss changes in the tissue landscape linked to CFTR-deficiency that may promote cancer development such as breakdowns in physical barriers, microbial dysbiosis and inflammation. It will also discuss molecular pathways and mechanisms that act upstream to modulate CFTR expression, such as by epigenetic silencing, as well as molecular pathways that act downstream of CFTR-deficiency, such as the dysregulation of the Wnt/β-catenin and NF-κB signaling pathways. Finally, it will discuss the emerging CFTR modulator drugs that have shown promising results in improving CFTR function in CF patients. The potential impact of these modulator drugs on the treatment and prevention of GI cancers can provide a new example of personalized cancer medicine.Keywords
Funding Information
- Whiteside Institute for Clinical Research (R01 CA134759-01A1)
- Mezin-Koats Colorectal Cancer Foundation (R01 CA134759-01A1)
- Essentia Health Systems (R01 CA134759-01A1)
- University of Minnesota Masonic Cancer Center (R01 CA134759-01A1)
- Randy Shaver Cancer Research & Community Fund (R01 CA134759-01A1)
- National Cancer Institute (R01 CA134759-01A1)
This publication has 152 references indexed in Scilit:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Allelic Variants Relate to Shifts in Faecal Microbiota of Cystic Fibrosis PatientsPLOS ONE, 2013
- Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United StatesJNCI: Journal of the National Cancer Institute, 2012
- Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotypeJournal of Experimental Medicine, 2012
- Functional Cftr in crypt epithelium of organotypic enteroid cultures from murine small intestineAmerican Journal of Physiology-Cell Physiology, 2012
- Meconium Ileus Caused by Mutations in GUCY2C, Encoding the CFTR-Activating Guanylate Cyclase 2CThe American Journal of Human Genetics, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Paneth cells constitute the niche for Lgr5 stem cells in intestinal cryptsNature, 2010
- The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host–microbial interactionsProceedings of the National Academy of Sciences, 2010
- Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinomaCancer, 2009
- Hypoxia inducible factor‐1 (HIF‐l)‐mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epitheliumThe FASEB Journal, 2008